头颈部鳞癌根治性放化疗:临床合作组「头颈癌个体化放疗」未选择队列结果
该研究回顾性分析了2008年9月至2016年3月在慕尼黑大学放疗科接受根治性放化疗的184例头颈部鳞癌患者,中位随访65个月,中位年龄64岁。中位放疗剂量70 Gy,90.2%同步化疗,多为丝裂霉素C/5-FU(符合ARO 95-06试验)。3年总生存率42.7%,局部、局部区域和远处失败率分别为29.8%、34.0%和23.4%。HPV相关口咽癌和较小肿瘤体积与更好的局部区域控制、无病生存和总生存显著相关。
要点
- 3年OS 42.7%,局部、局部区域、远处失败率分别为29.8%、34.0%、23.4%。
- HPV相关口咽癌和小肿瘤体积与更好的LR控制、DFS和OS显著相关。
- 低血红蛋白与DFS和OS受损显著相关(单因素分析)。
核心结论
- 该未选择单中心HNSCC队列的肿瘤控制率和生存率与既往报道相比具有优势。
- HPV相关口咽癌和较小肿瘤体积是局部区域控制、DFS和OS的显著有利因素。
研究设计与样本
- 回顾性单中心队列研究,纳入2008年9月至2016年3月在LMU慕尼黑放疗科接受dCRT的口腔、口咽、下咽或喉部HNSCC患者。
- 共184例患者,中位随访65个月,中位年龄64岁。
主要发现
- 中位放疗剂量70 Gy,90.2%患者接受同步化疗,多为丝裂霉素C/5-FU(符合ARO 95-06试验)。
- 3年总生存率42.7%,局部失败率29.8%,局部区域失败率34.0%,远处失败率23.4%。
- 多因素分析显示HPV相关口咽癌和较小肿瘤体积与显著改善的局部区域控制率、DFS和OS相关。
- 单因素分析显示较低血红蛋白水平与DFS和OS受损显著相关。
- 淋巴结受累范围与远处失败、DFS和OS相关;92例(50%)患者治疗符合ARO 95-06试验, corroborating该试验结果。
关键数值与推荐
- dCRT中位剂量70 Gy,同步化疗比例90.2%,方案多为丝裂霉素C/5-FU。
- 3年OS 42.7%,局部失败率29.8%,局部区域失败率34.0%,远处失败率23.4%。
- HPVOPC和较小GTV与显著改善的局部区域控制、DFS和OS独立相关(多因素分析)。
临床怎么用
- 该队列结果可用于与既往报道比较,并为基于分子遗传分析的转化研究提供临床数据基础。
- HPV相关口咽癌和较小肿瘤体积提示更好的预后,可能有助于风险分层。
局限性
- 回顾性单中心未选择队列设计。
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Definitive chemoradiotherapy (dCRT) is a standard treatment for patients with locally advanced head and neck cancer. There is a clinical need for a stratification of this prognostically heterogeneous group of tumors in order to optimize treatment of individual patients. We retrospectively reviewed all patients with head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, or larynx, treated with dCRT from 09/2008 until 03/2016 at the Department of Radiation Oncology, LMU Munich. Here we report the clinical results of the cohort which represent the basis for biomarker discovery and molecular genetic research within the framework of a clinical cooperation group. METHODS: Patient data were collected and analyzed for outcome and treatment failures with regard to previously described and established risk factors. RESULTS: We identified 184 patients with a median follow-up of 65 months and a median age of 64 years. Patients received dCRT with a median dose of 70 Gy and simultaneous chemotherapy in 90.2% of cases, mostly mitomycin C / 5-FU in concordance with the ARO 95-06 trial. The actuarial 3-year overall survival (OS), local, locoregional and distant failure rates were 42.7, 29.8, 34.0 and 23.4%, respectively. Human papillomavirus-associated oropharynx cancer (HPVOPC) and smaller gross tumor volume were associated with significantly improved locoregional tumor control rate, disease-free survival (DFS) and OS in multivariate analysis. Additionally, lower hemoglobin levels were significantly associated with impaired DFS und OS in univariate analysis. The extent of lymph node involvement was associated with distant failure, DFS and OS. Moreover, 92 patients (50%) of our cohort have been treated in concordance with the ARO 95-06 study, corroborating the results of this study. CONCLUSION: Our cohort is a large unselected monocentric cohort of HNSCC patients treated with dCRT. Tumor control rates and survival rates compare favorably with the results of previously published reports. The clinical data, together with the available tumor samples from biopsies, will allow translational research based on molecular genetic analyses.
引用
- Schüttrumpf L, Marschner S, Scheu K, et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". Radiat Oncol. 2020. PMID: 31906998. doi:10.1186/s13014-019-1452-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。